Connect with us

MDMA

News You Might Have Missed – July 26, 2021

The article News You Might Have Missed – July 26, 2021 was originally published on Microdose.

Welcome to the News You Might Have Missed, a weekly roundup…

Published

on

The article News You Might Have Missed – July 26, 2021 was originally published on Microdose.

Welcome to the News You Might Have Missed, a weekly roundup of news items to help you catch up and stay informed.

It was a busy week with lots of news, have a look and see you next Monday for another update.

Field Trip Health Ltd. Obtains Conditional Approval to List on Nasdaq

The company has received conditional approval from The NASDAQ Stock Market LLC to list its issued and outstanding common shares on the NASDAQ Global Select Market. Read more

Cybin Announces Conditional Listing Approval from NYSE American

Doug Drysdale, Cybin’s CEO “Conditional listing approval on the NYSE American is an important milestone in Cybin’s growth journey. We expect expanded access to investors to further fuel our mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions.” Read more

PharmaDrug Announces Stock Ticker Symbol Change to (CSE: PHRX)

The company announced that it will change its ticker symbol from “BUZZ” to “PHRX”. The Company expects the symbol change to take effect on August 3, 2021. The change in the ticker symbol is being made to provide greater visibility with respect to the long-term strategy of the Company. Read more

Levitee Labs Signs Definitive Agreements to Acquire Clinics, Pharmacies, and a Telemedicine Company

Pouya Farmand, Chief Executive Officer of Levitee, commented, “the Agreements we have entered today are integral to our growth strategy and goal of building a platform that will set a new standard for substance abuse and mental health treatment in Canada. Read more

Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds

The company announced the filing of a new patent for MDMA-like compounds further expanding its robust portfolio of novel compounds. Read more

PharmaTher Expands Patent Portfolio with Filing of Patent Application for Novel Ketamine Formulation

The company has filed a provisional patent application outlining a novel formulation of ketamine for intradermal administration as a potential treatment for mental health, neurological, and pain disorders. Read more

Tryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia

The company announced its plans to conduct a Phase 2a clinical trial with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School. Read more

Small Pharma Establishes Psychedelic-assisted Therapy Training Program

The company has launched a training program to educate psychologists on the process required for the support and completion of Small Pharma’s DMT-assisted therapy clinical trials. Read more

Read More

Trending